Adma Biologics (ADMA) EBT (2011 - 2025)

Adma Biologics has reported EBT for 13 years, with the latest figure at $61.6 million in Q4 2025.

• For the quarter ending Q4 2025, EBT rose 77.44% year-over-year to $61.6 million; the trailing twelve-month figure through Dec 2025 stood at $182.7 million (up 45.3% YoY), and the FY2025 full-year result was $182.7 million, up 45.29% from the prior year.
• EBT for Q4 2025 stood at $61.6 million, up from $47.5 million in the prior quarter.
• The five-year high for EBT was $61.6 million in Q4 2025, with the low at -$18.8 million in Q2 2021.
• Historically, EBT has averaged $8.9 million across 5 years, with a median of -$1.9 million in 2023.
• Annual changes were most pronounced in 2021 — EBT retreated 10.0% — and 2024, when it soared 1332.71%.
• Adma Biologics' EBT stood at -$16.5 million in 2021, then grew by 28.55% to -$11.8 million in 2022, then jumped by 189.84% to $10.6 million in 2023, then jumped by 227.67% to $34.7 million in 2024, then jumped by 77.44% to $61.6 million in 2025.
• The last three EBT figures came in at $61.6 million (Q4 2025), $47.5 million (Q3 2025), and $40.1 million (Q2 2025), per Business Quant data.